Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Karus Therapeutics Appoints Scientific Advisory Board

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Company announces move to new Oxford facilities.

Karus Therapeutics has announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development.

The appointment of Karus’s SAB reflects the Company’s recent expansion and move to fully-integrated research and office facilities near Oxford.

Last month, Karus relocated all its operations to new headquarters at Milton Park, Oxfordshire.

The move provides the Company with over 400 sqm of chemistry and biology laboratories, integrated with a corporate headquarters in a world leading biotechnology cluster.

The newly appointed SAB will support the Company’s continued R&D progress and comprises leading R&D professionals from academia and the pharma industry.

The SAB will operate under the direction of Karus’s Chief Scientific Officer, Dr Stephen Shuttleworth and members include:

• Dr James Bristol is a life-science adviser with 32 years senior R&D experience at major pharma companies, including SVP Worldwide Drug Discovery Research at Pfizer and senior R&D positions at Parke-Davis and Schering-Plough;
• Dr Fritz Frickel is an advisor to life-science companies. He was formerly SVP R&D and acting CEO of Alantos (acquired by Amgen), SVP Research at Abbott, Worldwide Head of Research at BASF and Head of Clinical, Pharmaceutical and Regulatory Development at Knoll;
• Dr Chris Reilly is a healthcare consultant who advises companies from discovery to early development.  He was previously Global VP Discovery Strategy and Performance and Head of Project Evaluation at AstraZeneca;
• Dr Phill Hawkins and Dr Len Stephens (Babraham Institute, Cambridge) are key opinion leaders in the area of PI3K biology, notably in the context of neutrophil function;
• Professor Bart Vanhaesebroeck (Queen Mary, University of London) leads the Centre for Cell Signalling at Barts Cancer Institute. He is a recognized opinion leader in the biology of PI3 kinases;
• Professor Jeff Evans (Beatson Institute, Glasgow) is a Professor of Translational Cancer Research and brings oncology drug discovery and development experience with clinical expertise in HDAC inhibitors; and,
• Dr Richard Groves (Guy's Hospital, London) is a consultant dermatologist with an active research programme investigating the causes and treatments for inflammatory skin diseases.

Commenting on the formation of the SAB, Dr Simon Kerry, Chief Executive of Karus, said: “We are very pleased to have attracted such a strong team to our scientific advisory board: they bring breadth and depth of knowledge to Karus, and we look forward to benefitting from their insight and guidance throughout our R&D programmes.

“Our new location in Oxfordshire is essential for Karus to grow: with a high quality team, our network of key opinion leaders and a supportive investor base, we are well positioned to advance our proprietary PI3K and HDAC6 inhibitor programmes into the clinic” he said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karus Therapeutics Appoints Penelope Ward as CMO
Dr Ward will drive Company’s HDAC6 and PI3K inhibitor programmes.
Tuesday, November 12, 2013
Karus Secures Series B Financing from a Syndicate of Leading VC Investors
New investment to support the development of Karus’s innovative PI3K and HDAC6 programmes through early human trials.
Thursday, January 17, 2013
Karus Therapeutics Announces Collaboration with Babraham Institute
Collaboration to explore PI3 kinase inhibitors in the treatment of inflammatory diseases.
Tuesday, December 18, 2012
Karus Commences Preclinical Development of Novel Immune and Inflammation Programmes
The Company aims to initiate clinical trials for both programmes in 2011.
Wednesday, November 03, 2010
Scientific News
Breaking Cell Barriers with Retractable Protein Nanoneedles
Adapting a bacterial structure, institute researchers have developed protein actuators that can mechanically puncture cells.
Gene Signature could Lead to a New Way of Diagnosing Lyme Disease
Lyme disease patients had distinctive gene signatures that persisted for at least three weeks, even after they had taken the antibiotics.
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
A Crystal Clear View of Biomolecules
Fundamental discovery triggers paradigm shift in crystallography.
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
NIH Seeks Research Applications to Study Zika in Pregnancy, Developing Fetus
Institute has announced that the new effort seeks to understand virus effect on reproduction and child development.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!